SURGERY PARTNERS Q2 2026 Earnings Preview: Recent $SGRY Insider Trading, Hedge Fund Activity, and More
Surgery Partners (SGRY) is set to report Q2 2026 earnings on Aug. 10 before market open, according to Finnhub. Analysts expect revenue of $846.97M and EPS of $0.06. The article cites insider selling only over the past six months, with 12 sales and no purchases, and notes mixed institutional 13F activity. Median analyst price target is $20.
How this was made
The 30-second read
Why it matters
Traders can use the stated consensus revenue and EPS as the benchmark for expectations into the Aug 10 pre-market release; however, the article provides no new operational or guidance datapoints beyond the preview.
Market read
Event-driven setup for earnings day positioning, anchored to consensus estimates and supplemented by insider-sale and 13F flow context.
What to watch
The article does not include guidance, margin drivers, backlog, or any quarter-specific operational details, which are typically the main drivers of post-earnings repricing.
Background
Quiver Quantitative frames Surgery Partners’ upcoming Q2 2026 earnings as an event to monitor, with consensus estimates plus recent insider and institutional activity.
Ticker impact
Article previews Surgery Partners’ Aug 10 pre-market earnings, citing consensus revenue of $846.97M and EPS of $0.06.
Near-term volatility likely around the Aug 10 pre-market earnings release versus the $846.97M revenue and $0.06 EPS expectations.
The only time-sensitive catalyst described is the scheduled earnings release with explicit consensus figures; insider activity and 13F flows are secondary and not definitive for the quarter’s outcome.
Market effects
Could affect sentiment for healthcare services providers if results materially diverge from consensus, but no sector-wide policy or regulatory change is described.
No regional macro or policy linkage is provided beyond the US earnings calendar.
No global demand, supply chain, or international regulatory catalyst is mentioned.
Counterpoint
Insider sales and mixed 13F flows may reflect diversification or portfolio rebalancing rather than a negative fundamental view, so the stock could still beat if operating metrics improve.
Key entities
- companySURGERY PARTNERS
SGRY, scheduled to report quarterly earnings on Aug 10 before market open, with consensus revenue $846,973,044 and EPS $0.06.
- insiderJASON ERIC EVANS
CEO reported 2 open-market sales in the past 6 months, totaling 31,862 shares.
- insiderDAVID T DOHERTY
CFO reported 2 open-market sales in the past 6 months, totaling 23,441 shares.
